Despite concerted efforts at investigating and disseminating the health risks of tobacco dependence, millions of Americans continue to smoke chronically. Drug abusers have twice the smoking rate of the general population and suffer increasingly costly quality of life and health consequences. For example, more than 80% of opioid dependent individuals on buprenorphine maintenance therapy smoke cigarettes. Recent research suggests that cigarette smoking adversely affects brain morphology, blood flow, biochemistry, and cognition. These smoking-related brain abnormalities resemble those observed in chronic drug use and involve major components of the reward circuit, implicated in the initiation and maintenance of all forms of addiction. Tobacco dependence is also related to higher levels of non-nicotinic drug use after drug abuse treatment. The impact of combined opioid and tobacco dependence on neurobiology and behavior has not been evaluated systematically, and its relations to high smoking relapse rates in this population are poorly understood. Recent research implicates abnormalities in the reward circuitry as major contributor to relapse in all drug use, but corresponding evidence from opioid users in tobacco dependence treatment is lacking. The main purpose of this component is to a) obtain magnetic resonance-derived and neurocognitive measures of the integrity of frontal-subcortical brain circuits in opioid dependent individuals on buprenorphine replacement therapy before their extended, innovative tobacco dependence treatment, b) determine if these measures diffenentiate successful and unsuccessful quitters, and c) determine their ability to pnedlct obacco dependence treatment response at 3, 6, 12, and 18 months after treatment randomization. Exploratory genetic studies will address the influence of select single nucleotide polymorphisms on the main neurobiological and treatment outcome measures and the impact of these polymorphisms on quit rates. The overarching purpose of this research is to enable - within the existing framework of the Center - the development of a unique collaboration among two productive research teams at UCSF that both have aimed for many years to help reduce the overall impact of drug abuse on society. This multidisciplinary component, performed as part of a larger clinical trial of extended and innovative tobacco dependence treatment, is expected to increase our understanding of the extent to which neurobiological and cognitive deficiencies as well as specific genotypes contribute to an individual's ability to maintain long-term tobacco abstinence.

Public Health Relevance

Our experience in quantitative measurements of neurobiological and cognitive consequences of drug abuse supports the Center's mission to develop more efficacious tobacco dependence treatment for difficult to treat populations and to focus sparse treatment resources in long-term follow-up on those with more vulnerable phenotypes and genotypes. The proposal will inform on functionally and behaviorally relevant brain dysfunction in drug abuse in general. It complements other research proposed by this Center and provides useful information for public education, health policy, and prediction of treatment outcome.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009253-19
Application #
8505430
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
19
Fiscal Year
2013
Total Cost
$603,006
Indirect Cost
$23,378
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Young-Wolff, Kelly C; Karan, Lori D; Prochaska, Judith J (2015) Electronic cigarettes in jails: a panacea or public health problem? JAMA Psychiatry 72:103-4
Ramo, Danielle E; Liu, Howard; Prochaska, Judith J (2015) A mixed-methods study of young adults' receptivity to using Facebook for smoking cessation: if you build it, will they come? Am J Health Promot 29:e126-35
Ramo, Danielle E; Young-Wolff, Kelly C; Prochaska, Judith J (2015) Prevalence and correlates of electronic-cigarette use in young adults: findings from three studies over five years. Addict Behav 41:142-7
Newville, Howard; Roley, Jason; Sorensen, James L (2015) Prescription medication misuse among HIV-infected individuals taking antiretroviral therapy. J Subst Abuse Treat 48:56-61
Martínez, Cristina; Guydish, Joseph; Le, Thao et al. (2015) Predictors of quit attempts among smokers enrolled in substance abuse treatment. Addict Behav 40:6-Jan
Nelson, J Craig; Baumann, Pierre; Delucchi, Kevin et al. (2014) A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 168:269-75
Lisha, Nadra E; Carmody, Timothy P; Humfleet, Gary L et al. (2014) Reciprocal effects of alcohol and nicotine in smoking cessation treatment studies. Addict Behav 39:637-43
Webber, Whitney L; van Erp, Brianna; Stoddard, Pamela et al. (2014) Determinants of exposure to secondhand smoke among Vietnamese adults: California Vietnamese Adult Tobacco Use Survey, 2007-2008. Prev Chronic Dis 11:E81
Cochran, Bryan N; Flentje, Annesa; Heck, Nicholas C et al. (2014) Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend 138:202-8
Satre, Derek D; Leibowitz, Amy S; Mertens, Jennifer R et al. (2014) Advising depression patients to reduce alcohol and drug use: factors associated with provider intervention in outpatient psychiatry. Am J Addict 23:570-5

Showing the most recent 10 out of 221 publications